Why Atopic Dermatitis Itches So Much and How to Get Relief

If you have atopic dermatitis, you already know that the itch is not like any ordinary itch. It is not the mild tickle of a mosquito bite that a quick scratch satisfies. It is relentless, burning, and bone-deep – an itch that intensifies at night precisely when you need to sleep, that builds into a cycle where scratching briefly relieves it only to make everything worse, and that can occupy every waking thought during a bad flare.

Atopic dermatitis is described clinically as “the itch that rashes” – a phrase that captures something essential. The itch is not a consequence of the rash. The itch often comes first. The rash is what the scratching produces.

Understanding why atopic dermatitis produces such extraordinary itching is not just academic. It is the key to understanding why conventional itch remedies often fail it, why antihistamines barely make a dent, and why the newest treatments – including biologics approved as recently as December 2024 – are transforming outcomes by targeting the itch pathway directly at its molecular source.

This article covers the complete science of atopic dermatitis itch – why it happens, what is actually firing in your nerves and immune system, and the full spectrum of evidence-based strategies from emollients to biologics that can actually provide meaningful relief.

The Biology of Itch in Atopic Dermatitis – Why It Is So Intense

The itch of atopic dermatitis is not ordinary histamine-mediated itch. This single fact explains why most people with the condition get little relief from antihistamines – and why the latest targeted therapies have been so transformative.

The Itch-Scratch Cycle – How It Starts and Why It Perpetuates Itself

The pathological mechanism of atopic dermatitis involves a complex interaction between skin barrier dysfunction and a predominantly T helper 2 (Th2)-skewed immune dysregulation. When the skin barrier – already compromised by filaggrin deficiency in genetically predisposed individuals – breaks down further, allergens and environmental irritants penetrate more deeply into the skin. This triggers immune activation. Immune cells flood the area. Inflammation begins. And the itch-scratch cycle takes hold.

Scratching damages the skin barrier further, worsens dryness, and increases the release of pro-inflammatory mediators – which generate more itch. More scratching causes more damage. More damage generates more inflammation. More inflammation drives more itch. Breaking this cycle is not just therapeutically important – it is physiologically essential to preventing the disease from spiraling into progressively worse states.

The Cytokine Itch Drivers – IL-31, IL-4, IL-13, and TSLP

The major mediators of itch in atopic dermatitis are cytokines – signaling proteins released by immune cells and keratinocytes that directly activate the sensory nerve fibers responsible for itch sensation.

IL-31 – the primary itch cytokine. IL-31 is currently regarded as the most significant pruritogen in atopic dermatitis. It is produced by Th2 cells – the immune cells dominantly activated in atopic dermatitis – and directly binds receptors on sensory neurons in the skin. When IL-31 activates its receptor (IL-31RA) on nerve fibers, those nerves fire itch signals to the brain. IL-31 can directly induce an itch sensation via its receptor complex on free nerve endings and simultaneously promotes other cells to release additional pruritogens – amplifying the signal.

TSLP – the alarm cytokine. Thymic stromal lymphopoietin (TSLP) is released by keratinocytes – skin surface cells – in response to allergen penetration or mechanical damage from scratching. TSLP activates transient receptor potential (TRP) sensory neurons directly – generating itch independent of immune cell involvement. It also drives further IL-31 production – creating a self-amplifying inflammatory and itch-generating loop.

IL-4 and IL-13 – the inflammation amplifiers. IL-4 and IL-13 enhance itching by sensitizing itch-sensory neurons to respond more intensely to direct pruritogens. They potentiate the effect of IL-31 and histamine – meaning the same amount of itch trigger produces a disproportionately large itch sensation. These cytokines are the primary targets of dupilumab – the first biologic approved for atopic dermatitis.

Sensory Nerve Hyperinnervation – More Nerve Endings, More Itch

One of the most striking structural features of atopic dermatitis skin is a dramatic increase in nerve fiber density at the skin surface.

In normal skin, both semaphorin 3A (Sema3A – a nerve repulsion factor) and nerve growth factor (NGF – a nerve elongation factor) are expressed in balance. In atopic dermatitis lesions, Sema3A expression decreases while NGF expression increases – causing sensory nerve fibers to grow into the skin surface layers they normally avoid. This hyperinnervation means that there are simply more nerve endings available to fire itch signals when stimulated – amplifying the perceived intensity of itch out of all proportion to the initial trigger.

In barrier-disrupted skin such as the lesional skin of atopic dermatitis, an increased density of intraepidermal nerves contributes to itch sensitization. This hyperinnervation is partly responsible for increased itch sensitivity. It also explains why patients with atopic dermatitis often experience itch from stimuli that would not register as itchy at all in a person with healthy skin – clothing, water temperature, sweat – a phenomenon called alloknesis.

The Mast Cell-Neuron Axis – The Itch Amplification Loop

Mast cells – immune cells resident in skin tissue – play a central amplifying role in atopic dermatitis itch. Activated cutaneous mast cells release powerful mediators including histamine, tryptase, substance P, and cytokines that directly stimulate corresponding receptors on itch-mediating sensory nerves.

But the relationship is bidirectional. Sensory nerves can release neuropeptides including substance P and vasoactive intestinal peptide (VIP) that stimulate mast cells to release further mediators – creating a reciprocal loop between nerves and immune cells that perpetuates and amplifies both neurogenic inflammation and itch.

This mast cell-neuron crosstalk operates largely independently of the histamine pathway – which explains why antihistamines that block H1 receptors provide minimal relief for most atopic dermatitis patients. The itch is being generated through multiple parallel pathways simultaneously – not through histamine alone.

TRP Ion Channels – The Molecular Itch Switches

Transient receptor potential (TRP) ion channels on sensory nerve fibers are the molecular switches that convert inflammatory chemical signals into electrical nerve impulses perceived as itch. Two channels are particularly important in atopic dermatitis:

TRPV1 – activated by heat, capsaicin, histamine, and the inflammatory mediator PAR2. Sensitization of TRPV1 by histamine or PAR2 agonists exacerbates itching – and TRPV1 expression is significantly upregulated in atopic dermatitis lesion skin biopsies, correlating with itch severity.

TRPA1 – activated by environmental chemicals, cold, certain bacterial products, and inflammatory cytokines including IL-13. TRPA1 integrates microbial and environmental signals including ligands from Staphylococcus aureus – the bacterium that colonizes most atopic dermatitis skin and directly worsens itch through TRPA1 activation. Research in animal models has confirmed that TRPA1 knockout significantly reduces scratching behavior and inflammation.

Why Histamine Is Not the Main Culprit

This is one of the most clinically important and practically impactful facts about atopic dermatitis itch. Antihistamines are generally not recommended for routine use with pruritic lesions in atopic dermatitis because itch is not primarily histamine-mediated. The dominant itch pathways in atopic dermatitis – IL-31, TSLP, substance P, TRP channel activation by S. aureus products and environmental triggers, and the mast cell-neuron loop – all operate independently of H1 receptor pathways.

Since itch does not involve histamine in atopic dermatitis, H1-antihistamines are ineffective for treating it. Any sedating antihistamine that appears to help does so through sedation – reducing the conscious experience of itch at night – rather than through any antipruritic mechanism.

Understanding this explains why antihistamine use in atopic dermatitis is largely futile for daytime itch – and why the new biologic treatments targeting IL-31 and IL-4/IL-13 pathways have been so dramatically more effective.

For more on how chronic inflammation drives multi-system disease, find out more in Naturem’s complete guide to the anti-inflammatory diet.

The Itch-Sleep-Stress Triangle – Why Nights Are the Worst

Atopic dermatitis itch follows a well-documented circadian pattern – consistently peaking in the late evening and nighttime hours. This is not simply perception or reduced distraction during quiet hours. It has a clear biological basis.

Skin temperature rises in the evening – vasodilation during the sleep-onset period increases blood flow to the skin, warming it and activating TRPV1 channels. Cortisol – which has anti-inflammatory properties – is at its daily lowest in the evening. Transepidermal water loss increases during sleep. And the circadian variation in immune cell activity means cytokine production peaks in the late evening – loading the skin with IL-31 and TSLP precisely when you are trying to sleep.

Sleep disruption from itch then feeds directly back into the inflammatory cycle. Chronic sleep deprivation increases systemic cortisol dysregulation, elevates inflammatory markers, and worsens immune dysregulation – creating a vicious loop where poor sleep worsens atopic dermatitis, which worsens sleep.

Stress activates this loop from another angle. Psychological stress triggers the hypothalamus-pituitary-adrenal axis – releasing cortisol and activating mast cells, which degranulate and release substance P and histamine. Stress also directly increases TSLP production from keratinocytes. The result is that emotional and psychological stress is a reliable, biologically-grounded trigger for atopic dermatitis flares – not merely a coincidence.

Evidence-Based Relief Strategies – From Daily Skincare to Biologics

Foundation Strategy 1 – Emollients – The Non-Negotiable Baseline

Moisturizers and emollients are the cornerstone of atopic dermatitis treatment at every stage – from mild to severe disease. The primary mechanism is restoration of the skin barrier – reducing transepidermal water loss and limiting allergen penetration. Less allergen penetration means less Th2 activation, less IL-31 production, and less itch.

The rules for maximum benefit:

• Apply immediately after bathing while skin is still damp – within 3 minutes of patting dry – to lock in moisture
• Choose ointments over creams where tolerated – ointments are more effective and better tolerated with less burning sensation in inflamed skin
• Use fragrance-free, dye-free formulations – fragrances are among the most common contact allergens worsening atopic dermatitis
• Apply generously and frequently – at least twice daily, more during flares
• Maintain emollient use even during remission – daily emollient application significantly reduces flare frequency when used preventively

Foundation Strategy 2 – Colloidal Oatmeal – Beyond Simple Moisturizing

Colloidal oatmeal is not simply a moisturizer. It contains avenanthramides – unique polyphenolic compounds with documented anti-inflammatory and antioxidant properties. These compounds reduce cytokine-driven skin inflammation while simultaneously protecting against oxidative stress in the skin.

A study with healthy patients found that treatment with a colloidal oat emollient significantly improved skin dryness, scaling, roughness, and itch intensity. A separate study comparing 1% colloidal oatmeal cream to a prescription barrier cream found equivalent efficacy and safety in 90 children with mild to moderate atopic dermatitis – at a fraction of the cost.

How to use: Add colloidal oatmeal bath packets to a lukewarm bath. Soak for 10 to 15 minutes. Pat – do not rub – dry. Apply emollient immediately. Alternatively, use topical colloidal oatmeal creams directly on itchy areas.

Foundation Strategy 3 – Dilute Bleach Baths – S. aureus Management

Staphylococcus aureus colonizes the skin of the majority of atopic dermatitis patients – and directly worsens itch through TRPA1 channel activation, filaggrin degradation, and induction of inflammatory cytokines. Reducing S. aureus burden is therefore a direct antipruritic strategy.

Bleach baths are championed by many dermatologists as a safe and effective home method to control eczema and reduce itch. The antimicrobial effect of dilute sodium hypochlorite (household bleach) reduces S. aureus colonization without causing antibiotic resistance.

The protocol: Add 1 teaspoon of regular unscented household bleach per gallon of bathwater (approximately 0.005% concentration). Soak for 5 to 10 minutes. Rinse with fresh water. Apply emollient immediately. Recommended 2 to 3 times weekly. Use only fragrance-free bleach and follow recommended amounts carefully. Always consult your dermatologist before beginning this regimen.

Foundation Strategy 4 – Wet Wrap Therapy – For Severe Flares

Wet wrap therapy is a clinical intervention for severe atopic dermatitis flares. It involves applying a topical corticosteroid or emollient to the affected skin, then wrapping in wet bandages followed by a dry layer. The wet wrap:

• Significantly enhances the penetration of topical medications into the skin
• Provides a physical barrier against scratching during the night
• Reduces transepidermal water loss dramatically
• Cools the skin – reducing heat-activated TRPV1 itch signaling

Wet wrap therapy is useful during severe flares and is typically used for 1 to 3 days under medical guidance. Prolonged use without supervision carries risks of skin thinning from enhanced corticosteroid absorption.

Medical Treatment – Topical Anti-Inflammatories

Topical corticosteroids (TCS) remain the first-line medical treatment for atopic dermatitis flares. Apply a topical corticosteroid twice daily to affected areas until improvement occurs – usually within a few days to 2 to 3 weeks. The appropriate potency is guided by the location and severity of the rash – lower potency for the face and skin folds, higher potency for the trunk and limbs. Long-term continuous use risks skin thinning and should be managed by a dermatologist.

Topical calcineurin inhibitors – tacrolimus and pimecrolimus – are steroid-free anti-inflammatory alternatives for sensitive areas including the face and eyelids. They work by inhibiting T-cell activation and reducing cytokine production without the skin-thinning risk of corticosteroids.

Topical JAK inhibitors – ruxolitinib cream – represent a newer topical approach that directly inhibits JAK/STAT signaling pathways downstream of multiple itch-generating cytokines simultaneously. Approved for mild to moderate atopic dermatitis.

Topical PDE4 inhibitors – roflumilast and crisaborole – reduce inflammation by inhibiting phosphodiesterase-4, lowering cyclic AMP breakdown and reducing Th2 cytokine production in the skin.

The Biologic Revolution – Targeting Itch at Its Molecular Source

The most significant development in atopic dermatitis treatment in a generation has been the arrival of targeted biologic medications that address the immune dysregulation driving the itch directly.

Dupilumab – Blocking IL-4 and IL-13 Pathways

Dupilumab binds the IL-4Rα receptor – blocking both IL-4 and IL-13 intracellular JAK/STAT signalling simultaneously. By suppressing both cytokines, dupilumab addresses the core Th2 immune dysregulation of atopic dermatitis – reducing inflammation, improving the skin barrier, and significantly reducing itch.

Dupilumab was FDA approved for adults with atopic dermatitis in March 2017 and has since been approved for adolescents, children aged 6 to 11 years, and infants aged 6 months and above. Its long safety record and broad efficacy across skin and itch outcomes make it the first-line biologic choice for most practitioners.

Nemolizumab – Targeting the Itch Pathway Directly

Nemolizumab is a humanized monoclonal antibody that binds directly to IL-31RA – blocking IL-31’s ability to activate the primary neurogenic itch pathway. Unlike dupilumab which reduces itch primarily by reducing inflammation, nemolizumab acts directly on the itch signaling pathway.

Clinical trials showed that 68% of nemolizumab patients achieved itch relief by day 2 – significantly faster than dupilumab’s itch response timeline. Nemolizumab was FDA approved for atopic dermatitis in December 2024 for patients aged 12 and above in combination with topical corticosteroids. It is particularly suited to patients whose primary burden is severe itch rather than skin lesion severity.

IL-13 Inhibitors – Tralokinumab and Lebrikizumab

Tralokinumab and lebrikizumab both bind IL-13 directly – preventing its interaction with receptors on keratinocytes and sensory neurons. Tralokinumab was approved in December 2021 for adults (later extended to adolescents), and lebrikizumab was FDA approved in September 2024 for adults and patients aged 12 and above.

Both agents show comparable efficacy to dupilumab for skin outcomes with a potentially lower incidence of dupilumab’s most common side effect – ocular surface disease. They may be preferred for patients who cannot tolerate dupilumab’s eye-related adverse effects.

JAK Inhibitors – Oral Systemic Option

Oral JAK inhibitors – upadacitinib (JAK1-selective), abrocitinib (JAK1-selective), and baricitinib (JAK1/JAK2) – provide once-daily oral suppression of multiple itch-generating cytokine pathways simultaneously. They are faster-acting than biologics and offer rapid itch relief – but carry a more complex safety profile that includes consideration of infection risk, thrombosis, and malignancy, requiring careful patient selection and monitoring.

In a head-to-head randomized controlled trial, abrocitinib 200mg daily was superior to dupilumab in improving itch response at week 2 – making it particularly valuable for patients needing rapid itch relief.

Practical Lifestyle Strategies for Itch Management

Clinical treatment is essential for meaningful itch control in atopic dermatitis. Alongside it, several evidence-supported lifestyle approaches provide meaningful additional benefit.

Keep nails short and skin covered at night. Scratching causes infection, barrier damage, and releases more pruritogens. Short nails minimize damage during involuntary nighttime scratching. Cotton gloves worn during sleep protect the skin.

Maintain cool bedroom temperature. Heat activates TRPV1 channels and vasodilates skin vessels – worsening nocturnal itch. A bedroom temperature of 18 to 19°C significantly reduces nighttime itch severity for many patients.

Choose skin-friendly clothing. 100% cotton, bamboo, or silk fabrics minimize friction and thermal activation of itch pathways. Avoid wool, synthetic materials, and tight elastic bands directly on affected skin.

Identify and avoid personal triggers. Common triggers include sweat, specific foods, pollen, pet dander, fragranced products, and stress. Trigger identification is individual – a patient diary documenting flare timing alongside food, activity, and environmental exposures helps map personal patterns over weeks.

Stress management. Progressive muscle relaxation was shown to improve pruritus and associated sleep loss in atopic dermatitis patients in a controlled trial. Mindfulness-based practices, breathing exercises, and regular physical activity all reduce the cortisol and neuropeptide responses that amplify itch.

Cold compress application. Cold temperatures inhibit TRPV1 channel activity and reduce local blood flow – providing temporary itch relief without any risk of barrier damage. A clean cool wet cloth applied to an acutely itchy area for 5 to 10 minutes can interrupt the itch-scratch cycle and provide enough relief to avoid further scratching.

Diet, Gut Health, and the Skin-Immune Connection

The gut-skin axis is an established and clinically meaningful pathway in atopic dermatitis. Short-chain fatty acids produced by beneficial gut bacteria reduce skin inflammation and enhance barrier function by promoting regulatory T cells and suppressing IL-6 and TNF-α – two inflammatory mediators that amplify the Th2 environment driving atopic dermatitis.

A diet rich in dietary fiber from vegetables, legumes, and whole grains feeds the microbiome that produces these protective SCFAs. Conversely, ultra-processed foods, refined carbohydrates, and excess sugar promote gut dysbiosis and systemic inflammation that may worsen atopic dermatitis severity.

Omega-3 fatty acids from fatty fish, flaxseeds, and walnuts reduce inflammatory eicosanoid production and support ceramide synthesis – directly addressing the lipid layer of the skin barrier that is compromised in atopic dermatitis.

Vitamin D deficiency is significantly more prevalent in atopic dermatitis patients than in the general population – and supplementation in deficient individuals has shown benefit in reducing flare severity and itch intensity.

Antioxidant-rich polyphenols from guava, berries, turmeric, and green tea reduce the oxidative stress that amplifies neurogenic inflammation in atopic dermatitis skin. These dietary approaches do not replace medical treatment – but they provide a meaningful supportive foundation that addresses the systemic inflammatory environment within which atopic dermatitis operates.

For those seeking traditional herbal support for systemic immune balance and anti-inflammatory resilience, Naturem’s Stamina Capsules combine adaptogenic herbs including Fructus Lycii, Morinda officinalis, and Rehmannia glutinosa – used in Traditional Vietnamese Medicine to support systemic vitality and immune homeostasis as a complementary daily foundation alongside medical care.

When to See a Dermatologist – Escalation Indicators

Seek prompt medical evaluation for atopic dermatitis itch if:

• Itch significantly disrupts sleep on most nights
• Over-the-counter emollients and colloidal oatmeal provide inadequate relief
• The rash is spreading to new areas or worsening despite skincare
• Signs of secondary infection appear – yellow crusting, oozing, warmth, fever
• Itch is impacting work, school, relationships, or mental health
• A child is scratching until bleeding or developing sleep disorders from itch
• Symptoms are not controlled with topical corticosteroids after 2 to 3 weeks

The 2024 American Academy of Dermatology guidelines strongly recommend monoclonal antibodies and JAK inhibitors for moderate to severe atopic dermatitis – a recommendation reflecting the transformative efficacy of these agents. Inadequate itch control in atopic dermatitis is no longer acceptable when effective options exist.

The Bottom Line

Atopic dermatitis itch is not an itch that simple remedies resolve. It is driven by a sophisticated neuroimmune network of cytokines – primarily IL-31, TSLP, IL-4, and IL-13 – acting on hyperinnervated, sensitized skin through TRP ion channels and a self-amplifying mast cell-neuron loop that operates largely outside the histamine pathway.

Relief requires matching the treatment to the biological mechanism. Emollients and barrier restoration address the upstream trigger. Colloidal oatmeal and bleach baths address the S. aureus amplification. Topical anti-inflammatories control flares. And the newest biologics – particularly nemolizumab and dupilumab – directly target the molecular itch circuitry in ways that no prior treatment has achieved.

The science of atopic dermatitis itch has advanced dramatically in the past decade. The treatments available in 2026 are the best that have ever existed. Access them with the guidance of a qualified dermatologist – and combine them with the lifestyle and nutritional foundations that reduce the inflammatory environment your skin must endure.

This article is for educational purposes only. It does not constitute personalized medical or dermatological advice. If you are experiencing significant itch or skin symptoms from atopic dermatitis, please consult a qualified dermatologist for proper evaluation and individualized treatment.

Frequently Asked Questions (FAQs)

References:

American Academy of Pediatrics. (2024). Treatment of atopic dermatitis. AAP. https://www.aap.org/en/patient-care/atopic-dermatitis/treatment-of-atopic-dermatitis/

American Academy of Pediatrics. (2024). Alternative treatments for atopic dermatitis. AAP. https://www.aap.org/en/patient-care/atopic-dermatitis/treatment-of-atopic-dermatitis/alternative-treatments/

Cleveland Clinic. (2024). Stop the itch: Home remedies to help manage eczema. https://health.clevelandclinic.org/home-remedies-for-eczema

Fassett, M. S., Cui, G., Nunberg, M., Shalek, A. K., & Locksley, R. M. (2022). IL-31-dependent neurogenic inflammation restrains cutaneous type 2 immune response in allergic dermatitis. Science Immunology, 7(67), eabi6887. https://www.science.org/doi/10.1126/sciimmunol.abi6887

GoodRx. (2026). OTC treatment for atopic dermatitis: What are your options? https://www.goodrx.com/health-topic/dermatology/otc-treatment-for-atopic-dermatitis

Hu, C., Li, W., Xu, L., & Zhang, H. (2025). Mast cell-neuron axis as a core mechanism in chronic pruritus of atopic dermatitis: From mechanistic insights to therapeutic targets. Frontiers in Immunology, 16, 1631478. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12604997/

Ikoma, A., Steinhoff, M., Ständer, S., Yosipovitch, G., & Schmelz, M. (2003). The neurobiology of itch. Nature Reviews Neuroscience, 9(1), 1-12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220552/

Mirali, S., Vakharia, P. P., & Silverberg, J. I. (2025). New topical and systemic treatments for atopic dermatitis. Clinical and Experimental Allergy, 55(9), 814-832. https://pmc.ncbi.nlm.nih.gov/articles/PMC12617513/

Naturem. (2026). Why you need an anti-inflammatory diet nutritionist: A complete guide. Naturem.us. https://naturem.us/blogs/healthy-advice/why-you-need-an-anti-inflammatory-diet-nutritionist-a-complete-guide

Naturem. (2026). 10 daily foods that could weaken your immunity. Naturem.us. https://naturem.us/blogs/healthy-advice/10-daily-foods-that-could-weaken-your-immunity

Naturem. (2026). Guava nutrition: Top health benefits and why you need it. Naturem.us. https://naturem.us/blogs/healthy-advice/guava-nutrition-top-health-benefits-and-why-you-need-it

Nemeth, V., Syed, H. A., & Evans, J. (2024). Eczema. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK538209/

Raap, U., Wichmann, K., Bruder, M., Ständer, S., Wedi, B., Kapp, A., & Werfel, T. (2013). Correlation of night-time pruritus and sleep quality in eczema. Acta Dermato-Venereologica, 93(5), 537-541. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526726/

Schut, C., Weik, U., Tews, N., Gieler, U., Deinzer, R., & Kupfer, J. (2016). Psychophysiological effects of stress management in patients with atopic dermatitis. Acta Dermato-Venereologica, 96(2), 170-174. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823020/

Sidbury, R., Alikhan, A., Bercovitch, L., Cohen, D. E., Darr, J. M., Drucker, A. M., Eichenfield, L. F., Fuxench, Z. C., Lio, P. A., Margolis, D. J., Paller, A. S., & Schneider, L. C. (2023). Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. Journal of the American Academy of Dermatology, 89(2), 137-151. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213003/

Silverberg, J. I., Yosipovitch, G., Simpson, E. L., Kim, B. S., Wu, J. J., Eckert, L., & Guillemin, I. (2023). Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with atopic dermatitis. Journal of the American Academy of Dermatology, 88(2), 385-394. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857157/

Suga, H., Miyagaki, T., & Sato, S. (2025). Advances in atopic dermatitis treatment: From pathogenesis to natural product-based therapies. Phytotherapy Research, 39(10), 4821-4845. https://pmc.ncbi.nlm.nih.gov/articles/PMC12504812/

Tay, B. Y., Abubakar, Z., Rosman, A. N., Ahmad, I., Tuan Sharif, S. E., & Mustaffa, N. (2025). Mechanisms of itch in atopic dermatitis. Journal of Clinical Medicine, 14(6), 1987. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915750/

Xie, J., Luo, Y., & Fang, H. (2025). The neuroimmune axis in atopic dermatitis: From pathogenic mechanisms to targeted neuroimmunotherapy. Journal of Inflammation Research, 18, 7829-7849. https://www.tandfonline.com/doi/full/10.2147/JIR.S578036